{"id":525887,"date":"2026-07-05T05:11:19","date_gmt":"2026-07-05T05:11:19","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/525887\/"},"modified":"2026-07-05T05:11:19","modified_gmt":"2026-07-05T05:11:19","slug":"eli-lilly-lly-stock-may-trade-at-a-cash-flow-discount-but-an-earnings-premium","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/525887\/","title":{"rendered":"Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. <\/p>\n

Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. <\/p>\n

A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. <\/p>\n

Expectations around the GLP-1 obesity and diabetes franchise can support a higher intrinsic value, while regulatory and pricing scrutiny, including recent attention on China trials and reimbursement, may limit how much investors are willing to pay for that growth. <\/p>\n

With Eli Lilly only passing 2 of 6 valuation checks, the broader picture leans more toward an expensive stock than a clear bargain, even with a DCF suggesting it trades about 23.7% below an intrinsic value estimate based on projected cash flows (2\/6 valuation score<\/a>). <\/p>\n

The issue now is whether Eli Lilly’s current price already reflects enough of that GLP-1 and pipeline optimism, or if the DCF style intrinsic value estimate still leaves a reasonable margin between market price and fundamentals. <\/p>\n

Eli Lilly delivered 56.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.<\/a> <\/p>\n

Is Eli Lilly a Bargain on Cash Flow? <\/p>\n

The Discounted Cash Flow (DCF) model here takes Eli Lilly’s projected cash flows and discounts them back to today using a 2 stage Free Cash Flow to Equity approach. Over the latest twelve months, Eli Lilly generated about $8.6b in free cash flow, and the model assumes those cash flows keep growing from this base rather than shrinking, which results in a higher intrinsic value than many mature pharmaceutical companies. <\/p>\n

On these assumptions, the DCF estimates an intrinsic value of about $1,591 per share, compared with a current share price around $1,213, implying the stock screens roughly 23.7% undervalued. The Medicare GLP-1 Bridge program, which broadens access to Eli Lilly’s obesity drugs on a capped copay, helps explain why cash flow expectations embedded in the model remain strong even though headline valuation multiples appear elevated. <\/p>\n

Overall, this DCF view suggests that Eli Lilly stock may be trading below the model’s estimate of intrinsic value. <\/p>\n

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 23.7%. Track this in your watchlist<\/a> or portfolio<\/a>, or discover 44 more high quality undervalued stocks<\/a>. <\/p>\n

Story continues <\/p>\n

\"LLY<\/a> LLY Discounted Cash Flow as at Jul 2026 <\/p>\n

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eli Lilly.<\/a> <\/p>\n

Is Eli Lilly Fairly Priced on Earnings? <\/p>\n

The P\/E ratio is a reasonable way to look at Eli Lilly because earnings remain a key focus for large, established pharmaceutical companies. At around 42.8x earnings, Eli Lilly trades at a sizable premium to the broader Pharmaceuticals industry average of about 15.4x and also above the peer group average of roughly 25.2x. <\/p>\n

However, the tailored fair P\/E ratio for Eli Lilly, which factors in elements such as its margins, scale and risk profile, sits lower at approximately 39.2x. That leaves the current multiple only modestly above this fair level, suggesting investors are paying up for the story, but not in a way that is out of line with what the company profile might justify. <\/p>\n

On balance, Eli Lilly stock looks priced roughly in line with what this P\/E framework would suggest is fair. <\/p>\n

\"NYSE:LLY<\/a> NYSE:LLY P\/E Ratio as at Jul 2026 <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

The Eli Lilly Narrative: What Would Justify Today’s Price? <\/p>\n

Simply Wall St Narratives for Eli Lilly pick up where the valuation checks leave off. They spell out which combinations of future growth, margins and earnings would need to play out for Eli Lilly’s stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Rather than focusing on a single multiple or model result, each narrative lays out the assumptions behind its fair value so you can compare them with actual results as they are reported. <\/p>\n

The community is split on Eli Lilly, with one side focused on how far the GLP-1 opportunity could run and the other on what happens if expectations cool. <\/p>\n

Bull case: roughly fairly valued <\/p>\n

“Advancements in research and development, particularly in neurodegenerative diseases (e.g., Alzheimer’s with Kisunla and donanemab), and a deep clinical pipeline with multiple late-stage readouts, position Eli Lilly to capture future multi-billion dollar market opportunities and support long-term revenue and margin expansion…” <\/p>\n

Read the full Bull Case<\/a> to see why Eli Lilly could be undervalued<\/a> <\/p>\n

Bear case: roughly fairly valued <\/p>\n

“P\/E ratio is currently quite high at the moment but is reflected based on projected growth…” <\/p>\n

Read the full Bear Case<\/a> to see why Eli Lilly could be overvalued<\/a> <\/p>\n

Do you think there’s more to the story for Eli Lilly? Head over to our Community to see what others are saying!<\/a> <\/p>\n

The Bottom Line <\/p>\n

For Eli Lilly, the Discounted Cash Flow (DCF) view points to meaningful intrinsic value upside, while the P\/E framework says the stock is now priced about right after a very strong multiyear move. That tension reflects different emphases, cash flow timing and capital needs on one side, market expectations and rich peers on the other, with the broader valuation checks still skewing weak despite the DCF signal. The crux from here is whether Eli Lilly can sustain the GLP-1 driven cash flow and pipeline execution that the intrinsic value view implies, or whether regulatory and pricing pressure keep the multiple capped and justify today’s premium without much further re-rating. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include LLY<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":525888,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,66067,78797,8829,227109,85,77209,46,239794],"class_list":["post-525887","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-cash-flows","tag-discounted-cash-flow","tag-eli-lilly","tag-eli-lilly-stock","tag-il","tag-intrinsic-value","tag-israel","tag-stock-screens"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/525887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=525887"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/525887\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/525888"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=525887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=525887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=525887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}